Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis.

Hartung DM, Bourdette D.

JAMA Neurol. 2019 Aug 26. doi: 10.1001/jamaneurol.2019.2445. [Epub ahead of print] No abstract available.

PMID:
31449289
2.

Association of Pharmacist Prescription of Hormonal Contraception With Unintended Pregnancies and Medicaid Costs.

Rodriguez MI, Hersh A, Anderson LB, Hartung DM, Edelman AB.

Obstet Gynecol. 2019 Jun;133(6):1238-1246. doi: 10.1097/AOG.0000000000003265.

PMID:
31135740
3.

Pharmacist Provision of Hormonal Contraception in the Oregon Medicaid Population.

Anderson L, Hartung DM, Middleton L, Rodriguez MI.

Obstet Gynecol. 2019 Jun;133(6):1231-1237. doi: 10.1097/AOG.0000000000003286.

PMID:
31135739
4.

Association of Pharmacist Prescription of Hormonal Contraception With Unintended Pregnancies and Medicaid Costs.

Rodriguez MI, Hersh A, Anderson LB, Hartung DM, Edelman AB.

Obstet Gynecol. 2019 May 9. doi: 10.1097/AOG.0000000000003265. [Epub ahead of print]

PMID:
31083123
5.

Pharmacist Provision of Hormonal Contraception in the Oregon Medicaid Population.

Anderson L, Hartung DM, Middleton L, Rodriguez MI.

Obstet Gynecol. 2019 May 9. doi: 10.1097/AOG.0000000000003286. [Epub ahead of print]

PMID:
31083122
6.

Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?

Hartung DM, Johnston K, Deodhar A, Bourdette DN, Cohen DM.

Am J Kidney Dis. 2019 Aug;74(2):256-262. doi: 10.1053/j.ajkd.2018.12.025. Epub 2019 Feb 11.

PMID:
30765104
7.

Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018.

Hartung DM, Johnston K, Geddes J, Leichtling G, Priest KC, Korthuis PT.

JAMA. 2019 Feb 12;321(6):607-609. doi: 10.1001/jama.2018.20391. No abstract available.

8.

Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D.

Hartung DM, Johnston KA, Irwin A, Markwardt S, Bourdette DN.

Health Aff (Millwood). 2019 Feb;38(2):303-312. doi: 10.1377/hlthaff.2018.05357.

PMID:
30715973
9.

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.

Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN.

JAMA Netw Open. 2018 Jun 1;1(2):e180482. doi: 10.1001/jamanetworkopen.2018.0482.

10.

Variations in prescription drug monitoring program use by prescriber specialty.

Sun BC, Lupulescu-Mann N, Charlesworth CJ, Kim H, Hartung DM, Deyo RA, John McConnell K.

J Subst Abuse Treat. 2018 Nov;94:35-40. doi: 10.1016/j.jsat.2018.08.006. Epub 2018 Aug 17.

PMID:
30243415
11.

A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations.

Hartung DM, Alley L, Leichtling G, Korthuis PT, Hildebran C.

Addict Behav. 2018 Nov;86:32-39. doi: 10.1016/j.addbeh.2018.04.020. Epub 2018 May 1.

PMID:
29754987
12.

Effects of a prior authorization policy for extended-release/long-acting opioids on utilization and outcomes in a state Medicaid program.

Keast SL, Kim H, Deyo RA, Middleton L, McConnell KJ, Zhang K, Ahmed SM, Nesser N, Hartung DM.

Addiction. 2018 Apr 20. doi: 10.1111/add.14248. [Epub ahead of print]

PMID:
29679440
13.

Uses of H.P. Acthar Gel in the Clinical Setting-Reply.

Hartung DM, Bourdette DN, Cohen DM.

JAMA Intern Med. 2018 Apr 1;178(4):583-584. doi: 10.1001/jamainternmed.2017.8545. No abstract available.

PMID:
29610884
14.

Elephant in the room.

Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar AA, Bourdette DN.

Ann Rheum Dis. 2019 Feb;78(2):e11. doi: 10.1136/annrheumdis-2018-213008. Epub 2018 Jan 23. No abstract available.

PMID:
29363509
15.

Effect of Automated Prescription Drug Monitoring Program Queries on Emergency Department Opioid Prescribing.

Sun BC, Charlesworth CJ, Lupulescu-Mann N, Young JI, Kim H, Hartung DM, Deyo RA, McConnell KJ.

Ann Emerg Med. 2018 Mar;71(3):337-347.e6. doi: 10.1016/j.annemergmed.2017.10.023. Epub 2017 Dec 13.

16.

Does Prescription Opioid Shopping Increase Overdose Rates in Medicaid Beneficiaries?

Sun BC, Lupulescu-Mann N, Charlesworth CJ, Kim H, Hartung DM, Deyo RA, McConnell KJ.

Ann Emerg Med. 2018 Jun;71(6):679-687.e3. doi: 10.1016/j.annemergmed.2017.10.007. Epub 2017 Nov 24.

17.

Pharmacists' Role in Opioid Safety: A Focus Group Investigation.

Hartung DM, Hall J, Haverly SN, Cameron D, Alley L, Hildebran C, O'Kane N, Cohen D.

Pain Med. 2018 Sep 1;19(9):1799-1806. doi: 10.1093/pm/pnx139.

18.

Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes.

Hartung DM, Kim H, Ahmed SM, Middleton L, Keast S, Deyo RA, Zhang K, McConnell KJ.

Subst Abus. 2018;39(2):239-246. doi: 10.1080/08897077.2017.1389798. Epub 2018 May 16.

PMID:
29016245
19.

Trends and Characteristics of US Medicare Spending on Repository Corticotropin.

Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN.

JAMA Intern Med. 2017 Nov 1;177(11):1680-1682. doi: 10.1001/jamainternmed.2017.3631. No abstract available.

20.

Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.

Hartung DM.

Neurotherapeutics. 2017 Oct;14(4):1018-1026. doi: 10.1007/s13311-017-0566-3. Review.

21.

Using prescription monitoring program data to characterize out-of-pocket payments for opioid prescriptions in a state Medicaid program.

Hartung DM, Ahmed SM, Middleton L, Van Otterloo J, Zhang K, Keast S, Kim H, Johnston K, Deyo RA.

Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1053-1060. doi: 10.1002/pds.4254. Epub 2017 Jul 19.

PMID:
28722211
22.

Impact of Hospital "Best Practice" Mandates on Prescription Opioid Dispensing After an Emergency Department Visit.

Sun BC, Lupulescu-Mann N, Charlesworth CJ, Kim H, Hartung DM, Deyo RA, John McConnell K.

Acad Emerg Med. 2017 Aug;24(8):905-913. doi: 10.1111/acem.13230. Epub 2017 Jul 26.

23.

Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.

Withycombe B, Ovenell M, Meeker A, Ahmed SM, Hartung DM.

J Clin Epidemiol. 2016 Sep;77:78-83. doi: 10.1016/j.jclinepi.2016.04.007. Epub 2016 Apr 22.

PMID:
27108488
24.
25.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866143
26.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866141
27.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866072
28.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866070
29.

The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program.

Kim H, Hartung DM, Jacob RL, McCarty D, McConnell KJ.

Psychiatr Serv. 2016 Apr 1;67(4):397-404. doi: 10.1176/appi.ps.201500116. Epub 2016 Jan 14.

30.

A chronic opioid therapy dose reduction policy in primary care.

Weimer MB, Hartung DM, Ahmed S, Nicolaidis C.

Subst Abus. 2016;37(1):141-7. doi: 10.1080/08897077.2015.1129526.

PMID:
26685018
31.

Rural-Urban Differences in Chronic Disease and Drug Utilization in Older Oregonians.

Goeres LM, Gille A, Furuno JP, Erten-Lyons D, Hartung DM, Calvert JF, Ahmed SM, Lee DS.

J Rural Health. 2016 Jun;32(3):269-79. doi: 10.1111/jrh.12153. Epub 2015 Oct 30.

32.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Hartung DM, Bourdette DN, Ahmed SM, Whitham RH.

Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24. Erratum in: Neurology. 2015 Nov 10;85(19):1728.

33.

The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.

Meeker AS, Herink MC, Haxby DG, Hartung DM.

Syst Rev. 2015 Mar 1;4:21. doi: 10.1186/s13643-015-0001-y. Review.

34.

Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication.

Hartung DM, Middleton L, Markwardt S, Williamson K, Ketchum K.

Clin Ther. 2015 Jan 1;37(1):114-123.e1. doi: 10.1016/j.clinthera.2014.10.025. Epub 2014 Nov 25.

PMID:
25465946
35.

Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.

Hartung DM, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR.

J Subst Abuse Treat. 2014 Aug;47(2):113-21. doi: 10.1016/j.jsat.2014.03.007. Epub 2014 Apr 13.

36.

Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.

Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M.

Ann Intern Med. 2014 Apr 1;160(7):477-83. doi: 10.7326/M13-0480.

37.

Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs.

Hartung DM, Zerzan J, Yamashita T, Tong S, Morden NE, Libby AM.

Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):87-94. doi: 10.1002/pds.3538. Epub 2013 Oct 21.

PMID:
24142840
38.

Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population.

Hartung DM, Middleton L, McFarland BH, Haxby DG, McDonagh MS, McConnell KJ.

Psychiatr Serv. 2013 Dec 1;64(12):1236-42. doi: 10.1176/appi.ps.005482012.

PMID:
23999754
39.

Breaking up is hard to do: lessons learned from a pharma-free practice transformation.

Evans D, Hartung DM, Beasley D, Fagnan LJ.

J Am Board Fam Med. 2013 May-Jun;26(3):332-8. doi: 10.3122/jabfm.2013.03.120268.

40.

A pilot study evaluating alternative approaches of academic detailing in rural family practice clinics.

Hartung DM, Hamer A, Middleton L, Haxby D, Fagnan LJ.

BMC Fam Pract. 2012 Dec 31;13:129. doi: 10.1186/1471-2296-13-129.

41.

Role of practice-based research networks in comparative effectiveness research.

Hartung DM, Guise JM, Fagnan LJ, Davis MM, Stange KC.

J Comp Eff Res. 2012 Jan;1(1):45-55. Review.

42.

Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Hartung DM, Middleton L, Svoboda L, McGregor JC.

CNS Drugs. 2012 Aug 1;26(8):707-16. doi: 10.2165/11634260-000000000-00000.

43.

Risk factors associated with linezolid-nonsusceptible enterococcal infections.

McGregor JC, Hartung DM, Allen GP, Taplitz RA, Traver R, Tong T, Bearden DT.

Am J Infect Control. 2012 Nov;40(9):886-7. doi: 10.1016/j.ajic.2011.11.005. Epub 2012 Feb 22.

44.

One practice's experiment in refusing detail rep visits.

Evans DV, Hartung DM, Andeen G, Mahler J, Haxby DG, Kraemer DF, Fagnan LJ.

J Fam Pract. 2011 Aug;60(8):E1-6.

PMID:
21814637
45.

Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users.

Morrato EH, Druss BG, Hartung DM, Valuck RJ, Thomas D, Allen R, Campagna E, Newcomer JW.

Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):66-75. doi: 10.1002/pds.2062. Epub 2010 Nov 15.

PMID:
21182154
46.

Effect of drug sample removal on prescribing in a family practice clinic.

Hartung DM, Evans D, Haxby DG, Kraemer DF, Andeen G, Fagnan LJ.

Ann Fam Med. 2010 Sep-Oct;8(5):402-9. doi: 10.1370/afm.1135.

47.

Metabolic screening in children receiving antipsychotic drug treatment.

Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW.

Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48. Erratum in: Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

PMID:
20368487
48.

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

PMID:
20048219
49.

Overview of clinical research design.

Hartung DM, Touchette D.

Am J Health Syst Pharm. 2009 Feb 15;66(4):398-408. doi: 10.2146/ajhp080300.

PMID:
19202050
50.

Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients.

Hartung DM, Wisdom JP, Pollack DA, Hamer AM, Haxby DG, Middleton L, McFarland BH.

J Clin Psychiatry. 2008 Oct;69(10):1540-7.

Supplemental Content

Loading ...
Support Center